Press Release

DiaSorin

DIASORIN S.P.A., THE BOARD OF DIRECTORS APPROVES THE RESULTS FOR THE FOURTH QUARTER OF 2007: REVENUES UP SHARPLY WITH A FURTHER SIGNIFICANT IMPROVEMENT IN PROFITABILITY

Fourth Quarter Financial Highlights:

- Consolidated net revenues total 51.2 million euros, up 18.7% compared with the same period in 2006 (+22.4% on a comparable foreign exchange translation basis);
- EBITDA* rise to 14.9 million euros, 42.4% more than the 10.5 million euros earned in the fourth quarter of 2006;
- EBIT grow to 11.4 million euros, for a gain of 69.2% compared with the 6.7 million euros reported in the fourth quarter of 2006;
- Consolidated net profit totals 6.1 million euros, increasing by 85.3% compared with the 3.3 million euros booked in the fourth quarter of 2006;
- Consolidated net borrowings decrease to 12.2 million euros, down from 15.9 million euros at September 30, 2007 and 34.7 million euros at December 31, 2006.

Highlights for the 2007 Fiscal Year†:

- Consolidated net revenues rise to 202.3 million euros, 12.6% more than the 179.8 million euros reported in 2006 (+15.1% on a comparable foreign exchange translation basis);
- EBITDA* grow to 60.0 million euros; net of extraordinary expense/income the figure is 64.0 million euros, up 21.8% compared with 2006, when they totaled 52.6 million euros net of extraordinary income (54.5 million euros including extraordinary income);
- EBIT increase to 46.1 million euros; net of extraordinary expense/income the figure is 50.0 million euros, for a gain of 30.8% compared with 38.3 million euros net of extraordinary income earned in 2006 (40.2 million euros including extraordinary income);
- Consolidated net profit totals 25.2 million euros, or 13.0% more than in 2006.

* The Company's defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

† The results for the full year, which will be approved by the Company's Board of Directors on March 19, 2008, will be the subject of an audit performed by Deloitte S.p.A.

Saluggia, February 14, 2008 – The Board of Directors of DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics, meeting under the chairmanship of Gustavo Denegri, approved the report on operations in the fourth quarter of 2007 presented by Carlo Rosa, the Company's Chief Executive Officer.

Review of the Consolidated Income Statement and Balance Sheet Highlights for the Fourth Quarter of 2006

The results achieved in the last three months of 2007 show that the positive trend that characterized the first three quarters of the year is continuing: revenues were up sharply, despite the appreciation of the euro versus the U.S. dollar, with profitability showing a substantial and steady improvement.

The fourth quarter of 2007 ended with **revenues increasing by 18.7%** compared with the same period the previous year. If the data are restated using constant exchange rates, revenues are up an even more impressive 22.4%. Once again, this improvement was driven primarily by higher sales of products based on CLIA (ChemiLuminescent Immuno Assay) technology, which rose by 34.5%, thanks to a steady growth of the installed base of LIAISON system (2,070 units at December 31, 2007, compared with 1,960 units at September 30, 2007 and 1,672 units at December 31, 2006), and by an expansion of the available assays menu, which produced an increase in the revenues generated by each machine. More specifically, 13 new products, including 10 specialties, earned the CE mark and 7 new products, all specialties, received FDA approval between 2006 and 2007. As a result, the contribution to total revenues provided by reagents based on **CLIA** technology increased to **53.4%.**

The revenue gain produced an improvement in all profitability indicators. The **gross profit** grew by 21.2%, rising from 26.2 million euros in the fourth quarter of 2006 to **31.7 million** euros in the last three months of 2007, for a return on sales of 62.0% (60.7% in 2006). **EBITDA** totaled **14.9 million** euros, or 42.4% more than in the fourth quarter of 2006, for a return on sales of 29.2% (24.3% in 2006). **Consolidated EBIT** for the fourth quarter of 2007 amounted to **11.4 million** euros, equal to 22.3% of revenues (15.6% in 2006).

The **net profit** rose to **6.1 million** euros, or 85.3% more than in the fourth quarter of 2006. The ratio of net profit to revenues also improved, increasing to 12.0%.

At December 31, 2007, consolidated net **borrowings** totaled **12.2 million** euros, down sharply from 15.9 million euros owed at September 30, 2007, and 34.7 million euros owed at December 31,

2006. During the fourth quarter of 2007, the Company repaid a portion amounting to 13.5 million euros of a financing facility it received from Interbanca .

Business Development

Breakdown of Revenues by Geographic Region

An analysis by geographic region of the revenues for the fourth quarter of 2007 shows that the rate of sales growth continued to accelerate in all regions, including both the countries where DiaSorin has been present for many years with a direct sales network, chief among them the United States, and those where its presence is more recent.

In Europe, revenues were up 16.9% in the fourth quarter of 2007, increasing from 26.2 million euros to 30.6 million euros. Outstanding results were achieved both in countries with a more mature market, such as France (+13.9%) and Spain (+15.8%) and in areas where the Group has been expanding rapidly, such as Great Britain (+28.2%) and Scandinavia (+34.3%).

In North America, where the development of the CLIA technology and the expansion of the installed base of Liaison system are relatively recent developments, sales continued to rise at a rapidly accelerating rate, confirming that this region is one of the markets of greatest strategic importance for the Group. In the fourth quarter of 2007, revenues totaled 11.9 million euros, or 28.1% more than in the same period a year earlier (+43.2% using constant exchange rates).

In markets other than Europe and North America, revenues grew by 13.5% to 8.6 million euros. Very impressive gains were achieved in countries where the Group established a presence only recently, such as Israel (revenues up 149.0%) and China (revenues more than tripled).

In the regions where the Group does not have a direct presence, choosing instead to operate through independent distributors, revenues were 41.1% higher than in the fourth quarter of 2006.

	Fourth Quarter		
(amounts in millions of euros)	2007	2006	Change
Europe	30.6	26.2	16.9%
North America (United States and Canada)	11.9	9.3	28.1%
Rest of the world	8.6	7.6	13.5%
Total	51.2	43.1	18.7%

Breakdown of Revenues by Technology

A breakdown of revenues in terms of the technologies offered by DiaSorin shows that in the fourth quarter of 2007 the increase was again driven by a rise in sales of products based on CLIA technology, which were up 34.5% in the closing quarter of 2007. This rate of growth was made possible by an expansion of the installed base of Liaison systems and a broadening of the portfolio of available products with the inclusion of specialty kits.

As a result, products based on CLIA technology accounted for 53.4% of total revenues at December 31, 2007, up significantly from 47.1% in the fourth quarter of 2006.

	Fourth Quarter	
% of revenues contributed	2007	2006
RIA	11.0%	13.6%
ELISA	24.0%	31.4%
CLIA (Liaison)	53.4%	47.1%
Equipment sales and other revenues	11.6%	7.9%
Total	100.0	100.0%

***

Significant Events Occurring the Fourth Quarter of 2007

During the closing quarter of 20007, DiaSorin took another decisive step forward toward entering the promising market for molecular diagnostics, when it signed a non-exclusive licensing agreement with Eiken Chemical Co. Ltd. for the use of **LAMP**[‡] (Loop-mediated Isothermal Amplification) technology.

DiaSorin thus gained access to the technologies and competencies it needs to develop an innovative equipment platform that can be used to automate molecular diagnostics tests. The main focus will be on infectious diseases, which is an area where DiaSorin already has a strong commercial base. A line of these tests, which will be available on a new equipment platform starting in 2011, will round out the vast spectrum of products that DiaSorin already offers on its Liaison system.

Operating Performance in the 2007 Fiscal Year

Even though the data are still preliminary, the DiaSorin Group ended 2007 with satisfactory results that exceeded expectations in terms both of revenues and profitability.

Revenues totaled about **202.3 million** euros, or about 12.6% more than in 2006. If the data are restated using constant exchange rates, the increase is 15.1%.

[‡] For additional information, please visit the Eiken Genome website (http://loopamp.eiken.co.jp/e/)

All profitability indicators improved considerably compared with 2006, particularly when the data are restated to eliminate the negative impact of nonrecurring items, which had opposite effects in 2006 and 2007. More specifically, as mentioned in previous disclosures, net extraordinary expense related to the charges incurred to quote the Company's shares on the Milan Online Stock Market totaled 4.0 million euros in 2007, as against net extraordinary income of 1.9 million euros in 2006, when the Company received a grant for research projects financed pursuant to Law No. 346/1998.
For all of 2007, **EBIT** and **EBITDA** amounted to **46.1 million** euros and **60.0 million** euros, respectively, and show increases of 30.8% and 21.8%, respectively, when the impact of the non recurring expense and income described above is eliminated.
Lastly, the Group's **net profit** grew to about **25.2 million** euros, or 13.0% more than the 22.3 million euros earned in 2006.

* * *

Pursuant to Paragraph 2 of Article 154 *bis* of the Uniform Financial Code, Andrea Alberto Senaldi, the Company's Corporate Accounting Documents Officer, declares that the accounting information provided in this press release is consistent with the data in the supporting documents and in the Company's other documents and accounting records.

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, Central and South America and Asia. It has more than 800 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: : infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology, fertility testing, etc.

Contacts:

Investor Relations Officer
Laura Villa
DiaSorin S.p.A.
Hlaura.villa@diasorin.itH
+39 0161487532
+39 348 15 11 542

Press Office
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
Hcaprioli@mailander.it
+39 335 590 14 02

CONSOLIDATED INCOME STATEMENT

	Fourth quarter		*Full year*	
(in thousands of euros)	**2007 (*)**	**2006 (*)**	**2007 (*)**	**2006**
Sales and service revenues	51,161	43,100	202,324	179,756
Cost of sales	(19,427)	(16,927)	(74,283)	(70,552)
Gross profit	**31,734**	**26,173**	**128,041**	**109,204**
	62.0%	*60.7%*	*63.3%*	*60.8%*
Sales and marketing expenses	(10,672)	(10,188)	(42,441)	(39,589)
Research and development costs	(3,253)	(2,470)	(11,397)	(9,161)
General and administrative expenses	(6,873)	(5,666)	(24,564)	(20,262)
	-40.7%	*-42.5%*	*-38.8%*	*-38.4%*
Other operating income (expenses)	467	(1,109)	(3,583)	18
non-current portion	-	-	*(4,508)*	*1,932*
EBIT	**11,403**	**6,740**	**46,056**	**40,210**
	22.3%	*15.6%*	*22.8%*	*22.4%*
Net financial income (expense)	(413)	(1,127)	(3,277)	(3,934)
Profit before taxes	**10,990**	**5,613**	**42,779**	**36,276**
Income taxes	(4,847)	(2,298)	(17,582)	(13,982)
Net profit	**6,143**	**3,315**	**25,197**	**22,294**
EBITDA (1)	**14,918**	**10,475**	**60,011**	**54,489**

(*) Unaudited data.

(1) The Company's defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

CONSOLIDATED BALANCE SHEET

(in thousands of euros)		*12/31/07*	*12/31/06*
ASSETS			
Property, plant and equipment		34.068	35,502
Goodwill		48.055	48,055
Other intangibles		17.186	14,750
Equity investments		123	123
Deferred-tax assets		8.747	8,357
Other non-current assets		345	245
	Total non-current assets	108.524	*107,032*
Inventories		35.485	30,891
Trade receivables		52.316	44,671
Accounts receivable from Group companies		21	
Other current assets		3.718	2,769
Cash and cash equivalents		8.366	8,718
	Total current assets	99.906	*87,049*
TOTAL ASSETS		**208,430**	**194,081**
LIABILITIES AND SHAREHOLDERS' EQUITY			
Share capital		55.000	50,000
Additional paid-in capital		5.925	4,425
Statutory reserve		639	207
Other reserves		778	2,854
Retained earnings (Loss carryforward)		32.755	7,957
Net profit for the year		25.197	22,294
	Total shareholders' equity	*120.294*	*87,737*
Borrowings		15.442	33,556
Provisions for employee severance indemnities and other employee benefits		19.026	19,154
Deferred-tax liabilities		929	672
Other non-current liabilities		2.140	3,047
	Total non-current liabilities	37.537	*56,429*
Trade payables		27.537	22,854
Accounts payable to Group companies		133	
Other current liabilities		13.992	12,508
Income taxes payable		3.862	4,633
Trade payables		5.075	9,920
	Total current liabilities	50.599	*49,915*
Total liabilities		**88.136**	**106,344**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		**208,430**	**194,081**

CASH FLOW STATEMENT

(in thousands of euros)	Fourth quarter (*)		Full year	
	2007	2006	2007 (*)	2006
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	22,483	16,453	8,718	6,116
Net cash from operating activities	6,569	7,213	30,328	33,976
Cash used in investing activities	(4,319)	(4,719)	(15,526)	(16,952)
Cash used in financing activities	(16,367)	(10,229)	(15,154)	(14,422)
Change in net cash and cash equivalents	*(14,117)*	*(7,735)*	*(352)*	*2,602*
CASH AND CASH EQUIVALENTS AT END OF PERIOD	8,366	8,718	8,366	8,718

(*) Unaudited data.